Abstract
This new, cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines.
The market for RNAi-based therapeutics is forecast to grow from 2013 onwards,
as the first products enter the marketplace, to generate sales in excess of
US$2.9 billion by 2020. The first siRNA-based therapeutics will capitalize on
the demand to treat viral infections and ocular conditions, and in the longer
term companies will be able to target niche areas of high unmet clinical need
such as cancer, cardiovascular disease, metabolic disorders, inflammatory and
neurological conditions.
Since the 1990s scientists across the world have begun to harness the power of
RNA interference (RNAi) to silence genes in a multitude of diseases. However,
many challenges face those aiming to develop RNAi-based therapies including
targeted delivery, the design and efficacy of gene silencing agents and the
minimization of off-target and immunogenic effects.
Today there are over 100 RNAi-based projects under investigation to treat
autoimmune and inflammatory diseases, cancer, cardiovascular disease, CNS
disorders, metabolic disorders, ocular conditions, and viral infectious
diseases. The majority of these projects are in the earliest discovery stages
(36%) or in preclinical studies (54%). Of the projects that have reached
clinical trials, only a handful have passed initial Phase I/II testing, with a
total of three being investigated in Phase II studies.
For executives working in industry and commerce, the need to understand the
issues, players and developers in this sector of high potential is essential.
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
is a 225+page report, published in July 2009 by UK pharma consultancy
PharmaVision which is available from Espicom Business Intelligence.
This new report will enable you to
- Assess the commercial potential of RNAi-based therapies in all of the key
therapeutic areas: cancer, CNS disorders, viral infectious diseases, ocular
diseases, cardiovascular, metabolic and other conditions
- Identify key pharma & delivery specialists advancing RNAi-based
therapeutics & diagnostics
- Gain an in-depth understanding of the technological & delivery issues
which face companies developing RNAi-based therapies
- Evaluate the options available for chemically and structurally modifying
RNAi silencing agents and delivering them to target tissues now & in the future
- Discover which companies are tackling efficacy and safety issues & are in
a prime position to exploit new opportunities
- Analyse how the market will evolve over the next decade highlighting key
trends, opportunities & challenges.
- The report answers keys questions such as
- Which companies & academic institutes are actively involved in RNAi-based
therapeutic research?
- What are the key areas of therapeutic focus for RNAi-based therapeutics in
the near & long-term?
- What are the key obstacles companies & delivery technologists need to
overcome to commercialize RNAi-derived therapies?
- How will delivery technologies drive the development of innovative
RNAi-based therapies in the future?
- Which RNAi technologies & agents are likely to win in the near-term &
long-term, & why?
- Where are the market opportunities now & in the future?
- When are RNAi-based medicines likely to reach the market?
- What do we predict will be the value of the RNAi-based therapeutics by
2015 & 2020?
| 
View Cart
